Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.71
Nov 13 • 3:59 PM ET Dollar change+0.09 Percentage change(5.56%)
Aftermarket Close
1.72
Aftermarket • 7:30 PM ET Dollar change+0.01 Percentage change(0.58%)
Index
-
Market Cap
18.94M
Enterprise Value
-2.52M
Income
-9.33M
Sales
3.74M
Book/sh
2.57
Cash/sh
1.94
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
14
IPO
Jun 15, 2012
P/E
-
Forward P/E
-
PEG
-
P/S
5.06
P/B
0.67
P/C
0.88
P/FCF
-
EV/EBITDA
-
EV/Sales
-0.67
Quick Ratio
11.36
Current Ratio
11.36
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-1.36
EPS next Y
-1.22
EPS next Q
-0.32
EPS this Y
18.93%
EPS next Y
11.31%
EPS next 5Y
-
EPS past 3/5Y
5.11% 22.70%
Sales past 3/5Y
58.12% -
EPS Y/Y TTM
-33.44%
Sales Y/Y TTM
-13.37%
EPS Q/Q
86.27%
Sales Q/Q
1898.77%
Insider Own
4.98%
Insider Trans
18.87%
Inst Own
26.30%
Inst Trans
-7.23%
ROA
-47.52%
ROE
-52.86%
ROIC
-44.09%
Gross Margin
98.42%
Oper. Margin
-269.06%
Profit Margin
-249.16%
SMA20
11.36%
SMA50
-7.86%
SMA200
-50.83%
Trades
Shs Outstand
11.07M
Shs Float
10.52M
52W High
12.37 -86.18%
52W Low
1.36 25.74%
Volatility
9.18% 7.91%
ATR (14)
0.14
RSI (14)
54.00
Beta
0.49
Rel Volume
0.12
Avg Volume
1.80M
Volume
215,123
Perf Week
8.92%
Perf Month
1.79%
Perf Quarter
-16.59%
Perf Half Y
-24.34%
Perf YTD
-78.70%
Perf Year
-39.36%
Perf 3Y
-38.49%
Perf 5Y
-91.55%
Perf 10Y
-97.17%
Prev Close
1.62
Price
1.71
Change %
5.56%
Consensus
Buy
Avg. Price Target
$5.00
Implied Upside
+192.4%
Analysts5incl. previous ratings
Rating Distribution3 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Apr 06, 2026Downgrade
HH.C. Wainwright
Buy → Neutral
Jun 24, 2021Initiated
CCantor Fitzgerald
Overweight$3+75.4%
Dec 10, 2020Upgrade
LLadenburg Thalmann
Neutral → Buy$3+75.4%
Jan 12, 2018Reiterated
HH.C. Wainwright
Buy$10 → $3+75.4%
Jan 11, 2018Downgrade
CCanaccord Genuity
Buy → Hold$11 → $2+17.0%
Dec 08, 2017Resumed
HH.C. Wainwright
Buy$10+484.8%
Oct 07, 2016Initiated
HH.C. Wainwright
Buy$25+1,362.0%
Jul 22, 2015Initiated
RROTH Capital
Buy$36+2,005.3%
Jun 23, 2015Initiated
CCanaccord Genuity
Buy$15+777.2%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patel Mahesh V.Chief Executive OfficerNov 13 '26Buy1.6025,00039,998211,495Nov 13 03:23 PM
Patel Mahesh V.Chief Executive OfficerNov 12 '26Buy1.5825,00039,490186,495Nov 13 03:23 PM
Higuchi John W.DirectorSep 30 '26Buy2.2315,97035,613241,365Oct 01 08:28 PM
Higuchi John W.DirectorSep 29 '26Buy2.159,03719,430225,395Oct 01 08:28 PM
Higuchi John W.DirectorSep 28 '26Buy2.1612,56127,132216,358Sep 30 08:38 PM
Higuchi John W.DirectorApr 07 '26Buy2.0340,00081,200203,797Apr 07 06:27 PM
Higuchi John W.DirectorApr 06 '26Buy2.05123,000252,150163,797Apr 06 07:01 PM
Patel Mahesh V.Chief Executive OfficerApr 06 '26Buy2.0325,00050,750160,679Apr 06 06:33 PM
Patel Mahesh V.Chief Executive OfficerApr 02 '26Buy2.0225,00050,500135,679Apr 02 05:05 PM
Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.
Co-FounderDr. Mahesh V. Patel Ph.D.
Principal Accounting Officer & Corporate ControllerMs. Krista Fogarty
Senior Vice President of Research & DevelopmentDr. Nachiappan Chidambaram Ph.D.
Vice President of SalesMr. Logan Morse
M.D.Dr. Anthony DelConte M. D.